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Background:  There  are  limited  data  on  the  impact  of smoking  status  on outcomes  after  isolated  coronary
artery  bypass  graft  (CABG)  surgery.
Methods:  Data  obtained  prospectively  between  June  2001  and December  2009 by the Australian  and
New  Zealand  Society  of Cardiac  and  Thoracic  Surgeons  Cardiac  Surgery  Database  Program  were  ret-
rospectively  analyzed.  Demographic  and  operative  data  were  compared  between  patients  who  were
non-smokers,  previous  smokers,  and  current  smokers.  The  independent  impact  of  smoking  status  on
14  short-term  complications  and  long-term  mortality  was  determined  using  binary  logistic  and  Cox
regression,  respectively.
Results: Isolated  CABG  surgery  was  performed  in  21 534  patients;  smoking  status  was recorded  in 21  486
(99.8%).  Of  these,  7023  (32.6%)  had  no previous  smoking  history,  11 183  (59.1%)  were  previous  smok-
ers,  and  3290  (15.2%)  were  current  smokers.  The  30-day  mortality  rate  was  1.8%  in  non-smokers,  1.5%
in  previous  smokers,  and  1.5%  in  current  smokers  (p = NS).  The  incidence  of peri-operative  compli-
cations  was  generally  similar  in the  three  groups,  but  current  smokers  were  at  an  increased  risk  of
pneumonia  (p < 0.001),  and  multisystem  failure (p =  0.003).  The  mean  follow-up  period  for  this  study
was  37  months  (range,  0–106  months).  After  adjusting  for differences  in patient  variables,  the inci-
dence  of late  mortality  was  higher  in previous  smokers  [hazard  ratio (HR),  1.73;  95% conﬁdence  interval
(CI),  1.47–2.05;  p  < 0.001] or current  smokers  (HR,  1.41;  95%  CI,  1.26–1.59;  p  < 0.001)  compared  to
non-smokers.
Conclusion:  Smoking  status  is  not  associated  with  early  mortality  after  isolated  CABG.  It  is,  however,
associated  with  an increased  risk  of pulmonary  complications  and  reduced  long-term  survival.
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Coronary artery bypass grafting (CABG) is a relatively safe
nd commonly performed cardiac operation with most recent
tudies quoting a mortality of 0.6–3.0% [1–6]. There are many
ell-established pre-operative risk factors including age, female
ex, diabetes, hypertension, metabolic syndrome, renal failure,
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New York Heart Association class, poor left ventricular ejection
fraction, extent of coronary disease, recent myocardial infarc-
tion, previous CABG, and urgent operation [4–10]. Despite these
investigations, the effect of smoking has been controversial and
opinions have changed within the past two decades. Some older
reports have suggested that CABG should be avoided in current
smokers due to increased risk of post-operative complications and
mortality, as well as early vein graft failure potentially leading
to early reoperation [11–13]. There is now increasing evidence
that smoking does not have an adverse impact on early outcomes
after CABG [2,3,14–16], and the main effect is on late outcomes
[15,17–22]. This evidence is limited as the case numbers have been
small, with calls for more meaningful studies [2]. In the context
vier Ltd. All rights reserved.
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f the continued prevalence of smoking, this study investigates
 larger number of patients to clarify the implications smoking
tatus has on early and late outcomes after CABG.
ethods
All patients undergoing isolated CABG surgery between 1 June
001, and 31 December 2009, at hospitals in Australia participat-
ng in the Australasian Society of Cardiac and Thoracic Surgeons
ASCTS) Cardiac Surgery Database were included in this study.
atients having concomitant valve surgery or other concurrent
ardiac surgical procedures were excluded from this study. All
 Victorian public hospitals that perform adult cardiac surgery –
he Royal Melbourne Hospital, The Alfred Hospital, Monash Medi-
al Centre, The Geelong Hospital, Austin Hospital, and St Vincent’s
ospital Melbourne – were involved in the prospective data collec-
ion during the entire period. Additionally, 14 cardiac surgical units
rom South Australia, New South Wales, and Queensland entered
he database project in the last 30 months of the study period and
ontributed 42.4% of the total patient numbers. Overall, 20 of 25
80%) public hospitals that perform cardiac surgery contributed
atients to this database. No private hospitals that perform cardiac
urgery participated in the current study.
The ASCTS database contained detailed information on patient
emographics, pre-operative risk factors, operative details, post-
perative hospital course, and morbidity and mortality outcomes.
hese data were collected prospectively using a standardized
ataset and deﬁnitions. Data collection and audit methods have
een previously described [23]. In the State of Victoria, the col-
ection and reporting of public hospital cardiac surgery data is
ompulsory and mandated by the State Government; hence it is
ll-inclusive. Data validation has been a major focus since the estab-
ishment of the ASCTS database. The data are subjected to both local
alidation and an external data quality audit program, which is
erformed on site to evaluate the completeness (deﬁned as <1%
issing data for any variable) and accuracy (97.4%) of the data
eld in the combined database. Audit outcomes are used to assist
n further development of appropriate standards. The Ethics Com-
ittee of each participating hospital had previously approved the
se of de-identiﬁed patient data contained within the database for
esearch and waived the need for individual patient consent.
In the current study, the preoperative characteristics, early out-
omes, and long-term survival of current or previous smokers were
ompared to those who were non-smokers. Patients were deﬁned
s smokers if they had smoked cigarettes within one month of
urgery. Patients who were not classiﬁed as current smokers but
ad a history conﬁrming any form of tobacco use in the past were
lassiﬁed as previous smokers.
Fourteen early post-operative outcomes were analyzed. These
ere: (a) 30-day mortality, deﬁned as death within 30 days of
peration; (b) permanent stroke, deﬁned as a new central neu-
ologic deﬁcit persisting for >72 h; (c) transient stroke, deﬁned
s a new transient neurologic deﬁcit that resolves completely
ithin 72 h (transient ischemic attack or reversible ischemic neuro-
ogic deﬁcit); (d) postoperative acute myocardial infarction (AMI),
eﬁned as at least two of the following: enzyme level elevation, new
ardiac wall motion abnormalities, or new Q waves on serial elec-
rocardiograms; (e) new renal failure, deﬁned as at least two of the
ollowing: serum creatinine increased to more than 200 mol/L,
oubling or greater increase in creatinine when compared with
he preoperative value, or new requirement for dialysis or hemoﬁl-
ration; (f) prolonged ventilation (>24 h); (g) multi-system failure;
eﬁned as concurrent failure of two or more of the cardiac, respira-
ory or renal systems for at least 48 h; (h) red blood cell transfusion;
i) gastrointestinal (GI) complications; deﬁned as post-operativeology 61 (2013) 336–341 337
occurrence of any GI complication; (j) deep sternal infection involv-
ing muscle and bone as demonstrated by surgical exploration and
one of the following: positive cultures or treatment with antibi-
otics; (k) pneumonia, deﬁned as positive cultures of sputum or
trans-tracheal aspirate and consistent with clinical ﬁndings of
pneumonia; (l) septicemia, deﬁned as positive blood cultures sup-
ported by at least two indices of clinical infection; (m)  return to
the operating theater for any cause; and (n) return to the operating
theater for bleeding.
Baseline pre-operative and intra-operative variables of patients
who were non-smokers, previous smokers, and current smokers
were compared. Categorical variables were compared using the
chi-square test across the three groups. When the chi-square test
across the groups was signiﬁcant, chi-square tests were performed
between each group to identify which groups were signiﬁcantly
different from each other. Continuous variables were compared
using the one way  analysis of variance (ANOVA). When signiﬁcant,
Tukey’s post hoc test was  applied to determine which groups were
signiﬁcantly different.
To assess the impact of smoking status on early outcomes,
logistic regression analysis was  used to adjust for 20 preop-
erative patient variables, with the outcome as the dependent
variable. Long-term survival status was  obtained from the Aus-
tralian National Death Index. Hence, follow-up was  complete in
all patients included in this study. The closing date was March
18, 2010. A Kaplan–Meier estimate of survival was obtained. The
role of smoking status on long-term survival was assessed by con-
structing a Cox proportional hazards model using smoking status
and other preoperative patient characteristics as variables. Con-
tinuous variables are presented as mean ± one standard deviation.
All calculated values of p were two-sided, and p < 0.05 was consid-
ered signiﬁcant. Statistical analysis was performed using SPSS® for
Windows version 17.0 (SPSS Inc., Chicago, IL, USA).
Results
CABG surgery was undertaken in 21 534 patients at 18
Australian institutions; smoking status was recorded in 21 486
(99.8%). Of these, 7023 (32.6%) had no previous smoking history,
11 183 (59.1%) were previous smokers, and 3290 (15.2%) were cur-
rent smokers. Pre-operative and demographic characteristics of
patients, stratiﬁed by smoking status are provided in Table 1. There
were some differences in intra-operative variables between the
three groups. These are summarized in Table 2.
Overall 30-day mortality and in-hospital mortality were 1.6%
and 1.8%, respectively. The unadjusted 30-day mortality rate was
1.8% in non-smokers, 1.5% in previous smokers, and 1.5% in current
smokers. This was not signiﬁcant on univariate analysis (p = 0.453).
The independent association of smoking status with other
post-operative outcomes is summarized in Table 3. The logistic
regression model predicting 30-day mortality is shown in Table 4.
This demonstrates that smoking status was not an independent
predictor for 30-day mortality. On univariate analysis, patients who
were current smokers had a signiﬁcantly higher length of intensive
care unit stay followed by previous smokers, and then non-smokers
(49.10 ± 125.61 h vs. 43.35 ± 71.67 h vs. 42.42 ± 125.61 h, p = 0.003).
Conversely, the post-procedure length of hospital stay was  lowest
in current smokers and highest in non-smokers (8.37 ± 7.65 days
vs. 8.60 ± 8.52 days vs. 8.87 vs. 10.37 days, p = 0.023).
The mean follow-up period for this study was  37 months (range,
0–106 months). Long-term survival is illustrated in Fig. 1. After
adjusting for differences in patient variables, the incidence of late
mortality was higher in both current smokers [odds ratio (OR),
1.41; 95% conﬁdence interval (CI), 1.26–1.59; p < 0.001] and pre-
vious smokers (OR, 1.73; 95% CI, 1.47–2.05; p < 0.001) compared to
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Table 1
Pre-operative characteristics, stratiﬁed by smoking status.
Preoperative variables Non-smoker Previous smoker Current smoker p
Total number of patients (%) 7023 11 183 p* 3280 p* p# –
Age (mean ± S.D) 67.91 ± 10.30 66.50 ± 9.86 <0.001 59.15 ± 10.44 <0.001 <0.001 <0.001
Chronic obstructive pulmonary disease (%) 555 (7.9) 1503 (13.4) <0.001 532 (16.2) <0.001 <0.001 <0.001
Diabetes mellitus (%) 2303 (32.8) 3768 (33.7) 0.232 954 (29.1) <0.001 <0.001 <0.001
Hypercholesterolemia (%) 5527 (78.7) 9189 (82.2) <0.001 2582 (78.7) <0.001 0.917 <0.001
Hypertension (%) 5488 (78.1) 8773 (78.4) 0.579 2304 (70.2) <0.001 <0.001 <0.001
Cerebrovascular disease (%) 723 (10.3) 1372 (12.3) <0.001 291 (8.9) <0.001 0.026 <0.001
Peripheral vascular disease (%) 588 (8.4) 1637 (14.6) <0.001 442 (13.5) 0.101 <0.001 <0.001
Renal  failure (%) 242 (3.4) 383 (3.4) – 90 (2.7) – – 0.128
Previous cardiac surgery (%) 252 (3.6) 462 (4.1) 0.066 69 (2.1) <0.001 <0.001 <0.001
Recent myocardial infarction (<21 days) (%) 3416 (48.6) 5935 (53.1) <0.001 2168 (66.1) <0.001 <0.001 <0.001
History of congestive heart failure (%) 1020 (14.5) 1884 (16.8) <0.001 501 (15.3) 0.029 0.387 <0.001
Unstable angina (%) 577 (8.2) 866 (7.7) 0.272 369 (11.3) <0.001 <0.001 <0.001
Left  main stenosis > 50% 1809 (25.8) 2846 (25.4) – 855 (26.1) – – 0.728
Leftventricularejectionfraction (EF) – – <0.001 – <0.001 <0.001 <0.001
Normal (EF > 0.60) (%) 3533 (50.3) 5093 (45.5) – 1330 (40.5) – – –
Mild  (EF > 0.45) (%) 2096 (29.8) 3525 (31.5) – 1055 (32.2) – – –
Moderate (EF 0.30–0.45) (%) 943 (13.4) 1805 (16.1) – 633 (19.3) – – –
Severe (EF < 0.30) (%) 239 (3.4) 526 (4.7) – 203 (6.2) – – –
Obesity (%) 2139 (30.5) 3807 (34.0) <0.001 1041 (31.7) 0.013 0.208 <0.001
New  York Heart Association classiﬁcation (%) – – 0.002 <0.001 <0.001 <0.001
Class  I (%) 2657 (37.8) 3924 (35.1) – 1343 (40.9) – – –
Class  II (%) 2351 (33.5) 3765 (33.7) – 986 (30.1) – – –
Class  III (%) 1108 (15.8) 1937 (17.3) – 482 (14.7) – – –
Class  IV (%) 386 (5.5) 619 (5.5) – 205 (6.3) – – –
Triple  vessel disease (%) 4953 (70.5) 8157 (72.9) 0.001 2371 (72.3) 0.529 0.060 0.003
Critical preoperative state (%) 504 (7.2) 763 (6.8) 0.323 293 (8.9) <0.001 0.002 <0.001
Status  – – 0.001 – <0.001 <0.001 <0.001
Elective (%) 4080 (58.1) 6759 (60.4) – 1520 (46.3) – – –
Emergency/salvage (%) 319 (4.5) 411 (3.7) – 205 (6.3) – – –
Urgent (%) 2624 (37.4) 4012 (35.9) – 1555 (47.4) – – –
EuroScore (additive) (mean ± S.D) 6.9 ± 3.3 6.6 ± 3.3 <0.001 6.0 ± 3.2 <0.001 <0.001 <0.001
* p-value of group in comparison to non-smoker.
# p-value of group in comparison to previous smoker.
Table 2
Intra-operative characteristics, stratiﬁed by smoking status.
Preoperative variables Non-smoker Previous smoker Current smoker p
Total number of patients (%) 7023 11 183 p* 3280 p* p# –
Off-pump procedures 584 (8.3) 869 (7.8) – 260 (7.9) – – 0.389
Number of distal anastomoses (mean ± S.D) 3.24 ± 1.06 3.23 ± 1.05 – 3.20 ± 1.05 – – 0.134
Cardiopulmonary bypass time (min) 88.41 ± 42.2 90.5 ± 42.0 0.002 90.0 ± 42.0 0.562 0.002 <0.001
Aortic  cross-clamp time (min) 64.0 ± 33.2 65.5 ± 34.1 0.011 65.0 ± 34.3 0.799 0.020 0.006
Internal mammary artery graft used (%) 6645 (94.6) 10,513 (94.0) – 3107 (94.7) – – 0.141
Left  internal mammary artery graft used (%) 5682 (80.9) 10,383 (92.8) – 3075 (93.8) – – 0.730
Right  internal mammary artery graft used (%) 875 (12.5) 1465 (13.1) – 444 (13.5) – – 0.235
* p-value of group in comparison to non-smoker.
# p-value of group in comparison to previous smoker.
Table 3
Early outcomes, stratiﬁed by smoking status.
Outcome Non smoker Previous
smoker
Current
smoker
Previous smoker Current smoker
Adjusted odds
ratio (95% CI)
p Adjusted odds
ratio (95% CI)
p
Permanent stroke (%) 60 (0.9) 78 (0.7) 30 (0.9) 0.83 (0.57–1.22) 0.337 1.33 (0.80–2.22) 0.272
Transient stroke (%) 26 (0.4) 52 (0.5) 9 (0.3) 1.29 (0.5–2.22) 0.360 0.83 (0.32–2.15) 0.700
Post-operative myocardial infarction (%) 52 (0.7) 74 (0.7) 32 (1.0) 0.85 (0.58–1.26) 0.425 0.95 (0.57–1.26) 0.854
New  renal failure (%) 253 (3.6) 429 (3.8) 104 (3.2) 0.98 (0.82–1.17) 0.809 0.99 (0.76–1.30) 0.961
Deep  sternal wound infection (%) 47 (0.7) 86 (0.8) 23 (0.7) 0.90 (0.60–1.34) 0.601 0.89 (0.50–1.61) 0.704
Pneumonia (%) 225 (3.2) 499 (4.5) 230 (7.0) 1.26 (1.06–1.50) 0.008 2.05 (1.66–2.54) <0.001
Septicemia (%) 67 (1.0) 110 (1.0) 34 (1.0) 0.95 (0.67–1.33) 0.745 1.15 (0.71–1.85) 0.581
Gastrointestinal complications (%) 73 (1.0) 137 (1.2) 31 (0.9) 1.22 (0.89–1.67) 0.227 1.27 (0.79–2.02) 0.323
Multi-system failure (%) 50 (0.7) 85 (0.8) 34 (1.0) 1.21 (0.80–1.82) 0.362 2.18 (1.30–3.65) 0.003
Red  blood cell transfusion 3015 (42.9) 4120 (36.8) 1098 (33.5) 0.97 (0.91–1.05) 0.468 0.92 (0.83–1.02) 0.114
Prolonged ventilation (%) 596 (8.5) 949 (8.5) 321 (9.8) 0.98 (0.87–1.12) 0.793 1.19 (1.01–1.42) 0.044
Return to theater (%) 353 (5.0) 565 (5.1) 149 (4.5) 1.01 (0.87–1.17) 0.915 1.05 (0.84–1.30) 0.698
Return to theater for bleeding (%) 176 (2.5) 263 (2.4) 70 (2.1) 0.92 (0.74–1.14) 0.430 0.94 (0.74–1.14) 0.677
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Table  4
Predictors of early and late mortality on multivariate analysis.
Preoperative variables 30-day mortality Late mortality
Odds ratio (95% CI) p-Value Odds ratio (95% CI) p-Value
Age 1.05 (1.03–1.06) <0.001 1.07 (1.06–1.07) <0.001
Smoking status – – – –
Non-smoker 1.00 – 1.00 –
Previous smoker 0.98 (0.74–1.29) 0.868 1.41 (1.26–1.59) <0.001
Current smoker 1.05 (0.76–1.44) 0.772 1.73 (1.47–2.05) <0.001
Female 1.21 (0.92–1.60) 0.168 1.00 (0.89–1.12) 0.986
Chronic obstructive pulmonary disease 1.05 (0.76–1.44) 0.772 1.28 (1.14–1.44) <0.001
Diabetes mellitus 1.01 (0.78–1.30) 0.957 1.23 (1.12–1.36) <0.001
Hypercholesterolemia 0.80 (0.61–1.06) 0.124 0.75 (0.67–0.84) <0.001
Hypertension 1.24 (0.90–1.71) 0.191 1.21 (1.07–1.37) 0.003
Cerebrovascular disease 0.84 (0.60–1.18) 0.321 1.26 (1.11–1.42) <0.001
Peripheral vascular disease 1.35 (1.01–1.82) 0.045 1.50 (1.34–1.68) <0.001
Renal  failure 1.83 (1.21–2.76) 0.004 2.32 (1.95–2.77) <0.001
Obesity 1.02 (0.78–1.34) 0.869 1.02 (0.92–1.14) 0.684
Recent myocardial infarction (<21 days) 1.55 (1.18–2.04) 0.002 1.06 (0.94–1.19) 0.378
History of congestive heart failure (%) 1.94 (1.48–2.56) <0.001 1.53 (1.37–1.70) <0.001
Unstable angina (%) 1.55 (1.14–2.09) 0.005 0.96 (0.83–1.12) 0.598
Left  main stenosis > 50% 1.28 (1.00–1.65) 0.049 1.13 (1.02–1.26) 0.021
Left  ventricular ejection fraction < 0.45 1.98 (1.52–2.58) <0.001 1.58 (1.42–1.76) <0.001
New  York Heart Association classiﬁcation III or IV 1.46 (1.12–1.89) 0.005 1.19 (1.08–1.32) 0.001
Triple  vessel disease 1.15 (0.85–1.57) 0.361 1.18 (1.05–1.33) 0.008
Non-elective procedure 1.62 (1.20–2.20) 0.002 1.10 (0.98–1.23) 0.106
Critical preoperative state 2.47 (1.83–3.33) 
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no greater risk of any complications compared to non-smokers.Fig. 1. Overall survival, stratiﬁed by smoking status.
on-smokers. A Cox regression model predicting late mortality is
ummarized in Table 4.
iscussion
The general paucity of information regarding smoking and peri-
perative risk has limited our ability to give effective advice on
atient suitability for surgery [24]. Cigarette smoking is a powerful
isk factor for coronary artery disease, myocardial infarction, and
ardiac causes of death. To date, its effect on outcomes after CABG
s not entirely clear. The early mortality in this analysis is com-
arable with that of other recent studies [2,3,14–16] and clearly
emonstrates that smoking status has no adverse impact on 30-day
ortality after CABG. Rather, late mortality is signiﬁcantly worse.
iven the ever burgeoning cardiac surgical patient population and<0.001 1.55 (1.34–1.80) <0.001
intractable problem of continued smoking within these patients
[24], it is a priority to clearly delineate the impact of smoking status.
The decision to perform CABG in a current smoker has
traditionally been controversial. Older studies have previously
demonstrated a reluctance to operate on the basis of smoking sta-
tus. The rationale behind this is poorer CABG outcomes due to
failure of vein graft patency and greater risks of post-operative com-
plications, mortality, and earlier need for reoperation which carries
its own  risks [11,13]. Surgeons have also put patients on the wait-
ing list on the basis they will quit smoking after as a bargaining tool
[12]. These reports contend that resources can be better allocated
to non-smokers who  have fewer complications and greater beneﬁt
from CABG. However, recent studies have refuted the premise that
smokers experience worse post-operative morbidity and mortality
[2,3,14–16].
Our results conﬁrm that CABG surgery does not appear to endan-
ger a smoker any more than non-smokers. On both univariate and
multivariate analysis, smoking had no inﬂuence on 30-day mor-
tality (Table 4). There were some key differences in the patient
demographics (Table 1). In particular, smokers were younger and
had a lower incidence of previously identiﬁed risk factors for CABG
such as diabetes, hypertension, renal failure, and previous cardiac
surgery which may  have partially accounted for the lack of dif-
ference in mortality between groups. Smokers also had a greater
incidence of recent myocardial infarction, left main stenosis, urgent
operation, and chronic obstructive pulmonary disease. Many of
these differences are present in previous studies [2,16] and make
interpretation of mortality rates difﬁcult based on univariate anal-
ysis alone. Our multivariate analysis corrects for many of these
differences and shows no difference in 30-day mortality with a
higher late mortality (Table 4).
Current smokers had more pulmonary complications, but the
data otherwise show no increase in non-pulmonary complications
in smokers compared to non-smokers (Table 3), consistent with
recent experience [2,15,25]. In addition, previous smokers hadThe similarity in post-operative complication proﬁle regardless of
smoking status may  be an explanation of why  there is no sig-
niﬁcant increase in mortality for smokers [2]. Furthermore, the
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resence of underlying lung disease appears to have little impact on
ost-operative mortality [15,26]. Surgeons often perceive a greater
ncidence of pulmonary complications in smokers as the reason
ot to offer the procedure until smoking cessation is achieved [13].
owever, smoking cessation is often a difﬁcult and protracted pro-
ess which may  delay the patient from receiving a much greater
eneﬁt from undergoing CABG, especially in light of these data sug-
esting a similar incidence of morbidity or mortality. Our study did
emonstrate, on univariate analysis, that length of intensive care
nit stay was higher in smokers. This is likely to reﬂect the fact
hat smokers more often presented with respiratory disease and
ad greater ventilator requirements in the post-operative period.
onversely, on univariate analysis, the post-procedure length of
ospital stay was lower in current smokers. This is likely to reﬂect
he fact that these patients presented with fewer co-morbidities
han other patients as reﬂected in the lower additive EuroScore
p < 0.001).
We  recognize that whilst smoking and having smoking-related
ung disease does not appear to increase risk of death after CABG,
eveloping pneumonia is still a signiﬁcant complication causing
orbidity for the patient. We  still advise smoking cessation at
east 6 weeks preoperatively, but not as a precluding factor for
urgery. Despite the similar rates of early outcomes, the contin-
ed adverse health effects from smoking on multiple organ systems
s well established and should not be ignored. This is reﬂected in
ong term follow-up of these patients. Increased late mortality after
ABG is well established in smokers [3,15,17–22], and is in con-
ensus with our data. Furthermore, these patients are more likely
o have cardiovascular-related morbidity and mortality as well as
reater need for reoperation for graft failure [20]. Finally, smoking
s a deﬁnitive risk factor for acute coronary syndrome and a risk
actor for chronic kidney disease which has been consistently asso-
iated with poorer outcomes [27,28]. The impact of smoking on
igh-risk groups such as diabetics requires further evaluation [29].
he implication is that patients undergoing CABG surgery should be
ncouraged to quit smoking. Importantly, surgery remains a good
otivator and high impact time for changing attitudes to smoking
nd cessation should be encouraged in all patients [30–32].
Our study demonstrates that in the Australian experience of iso-
ated CABG, post-operative outcomes are not signiﬁcantly affected
y the smoking status of patients. This will further our understand-
ng and help dispel any previous discrepancies. The limitations
f this study are principally related to the retrospective nature
f our data, with confounding factors possibly not identiﬁed. In
ddition, there was no stratiﬁcation for number of packet years
moked or biochemical conﬁrmation of smoking status. By dividing
roups into current, previous, and never smokers, we  hope to elim-
nate some of the inconsistencies of polarizing into either current
mokers or never smokers alone. Our database also only contained
nformation on all-cause mortality and we were not able to dis-
inguish between cardiac and non-cardiac death. This limitation
hould be addressed in future prospective studies. The multi-
nstitutional nature of our data also precludes us from obtaining
nformation on post-operative smoking cessation status, a factor
hat is likely to have prognostic implications.
In summary, this study conﬁrms the observation that smoking
s not predictive of adverse outcomes after isolated CABG surgery
nd is not associated with increased 30-day mortality. This rep-
esents an increased opportunity for current smokers to access
ABG procedures. Importantly, smoking status alone should not
reclude these patients from receiving these operations. However,
e emphasize that this should not translate into ignorance of con-inued smoking in patients undergoing surgery. Given the adverse
ffect of smoking on overall cardiovascular morbidity and mortal-
ty as well as on late post-operative mortality, patients should still
e encouraged, and even assisted in endeavors to quit smoking.
[
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